Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY 3401016
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BAY 3401016 is a monoclonal antibody developed by Bayer and Evotec SE that targets semaphorin 3A (SEMA3A). It acts as a SEMA3A antagonist, modulating the activity of semaphorin pathways. The drug is being investigated primarily for hereditary nephritis (Alport syndrome), with additional preclinical development for acute kidney injury. As of the latest updates, it has reached Phase I clinical trials in hereditary nephritis and remains in preclinical stages for acute kidney injury. The therapeutic rationale centers on inhibiting SEMA3A to potentially ameliorate or prevent progression of kidney diseases[1][2][5][7].
02
Targets
SEMA3A (Semaphorin-3A)
Beyond the preview
Go deeper on BAY 3401016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY 3401016.